{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T15:49:42Z","timestamp":1782575382580,"version":"3.54.5"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T00:00:00Z","timestamp":1782518400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T00:00:00Z","timestamp":1782518400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Childs Nerv Syst"],"DOI":"10.1007\/s00381-026-07376-9","type":"journal-article","created":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T15:36:04Z","timestamp":1782574564000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Pediatric medulloblastoma"],"prefix":"10.1007","volume":"42","author":[{"given":"Kazuhiro","family":"Sabet","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hope","family":"Lovell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriana","family":"Fonseca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,27]]},"reference":[{"issue":"Suppl 3","key":"7376_CR1","doi-asserted-by":"publisher","first-page":"iii1","DOI":"10.1093\/neuonc\/noac161","volume":"24","author":"QT Ostrom","year":"2022","unstructured":"Ostrom QT, Price M, Ryan K et al (2022) CBTRUS statistical report: pediatric brain tumor foundation childhood and adolescent primary brain and other central nervous system tumors diagnosed in the United States in 2014-2018. Neuro-oncol 24(Suppl 3):iii1\u2013iii38. https:\/\/doi.org\/10.1093\/neuonc\/noac161","journal-title":"Neuro-oncol"},{"issue":"5","key":"7376_CR2","doi-asserted-by":"publisher","first-page":"613","DOI":"10.3171\/2018.11.PEDS18506","volume":"23","author":"DW Fults","year":"2019","unstructured":"Fults DW, Taylor MD, Garzia L (2019) Leptomeningeal dissemination: a sinister pattern of medulloblastoma growth. J Neurosurg Pediatr 23(5):613\u2013621. https:\/\/doi.org\/10.3171\/2018.11.PEDS18506","journal-title":"J Neurosurg Pediatr"},{"issue":"24","key":"7376_CR3","doi-asserted-by":"publisher","first-page":"3680","DOI":"10.3390\/diagnostics13243680","volume":"13","author":"N Mushtaq","year":"2023","unstructured":"Mushtaq N, Ul Ain R, Hamid SA, Bouffet E (2023) Evolution of systemic therapy in medulloblastoma including irradiation-sparing approaches. Diagnostics (Basel) 13(24):3680. https:\/\/doi.org\/10.3390\/diagnostics13243680","journal-title":"Diagnostics (Basel)"},{"issue":"11","key":"7376_CR4","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1200\/JCO.2009.27.4324","volume":"29","author":"PA Northcott","year":"2011","unstructured":"Northcott PA, Korshunov A, Witt H et al (2011) Medulloblastoma comprises four distinct molecular variants. J Clin Oncol 29(11):1408\u20131414. https:\/\/doi.org\/10.1200\/JCO.2009.27.4324","journal-title":"J Clin Oncol"},{"issue":"8","key":"7376_CR5","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","volume":"23","author":"DN Louis","year":"2021","unstructured":"Louis DN, Perry A, Wesseling P et al (2021) The 2021 WHO classification of tumors of the Central Nervous System: a summary. Neuro Oncol 23(8):1231\u20131251. https:\/\/doi.org\/10.1093\/neuonc\/noab106","journal-title":"Neuro Oncol"},{"issue":"5","key":"7376_CR6","doi-asserted-by":"publisher","first-page":"2225","DOI":"10.21873\/anticanres.15703","volume":"42","author":"T Sursal","year":"2022","unstructured":"Sursal T, Ronecker JS, Dicpinigaitis AJ et al (2022) Molecular stratification of medulloblastoma: clinical outcomes and therapeutic interventions. Anticancer Res 42(5):2225\u20132239. https:\/\/doi.org\/10.21873\/anticanres.15703","journal-title":"Anticancer Res"},{"issue":"2","key":"7376_CR7","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.phoj.2023.05.001","volume":"8","author":"S Sarvode","year":"2023","unstructured":"Sarvode S, Gajjar A (2023) Review of the impact of molecular analysis on the therapy of medulloblastoma. Pediatr Hematol Oncol J 8(2):121\u2013128. https:\/\/doi.org\/10.1016\/j.phoj.2023.05.001","journal-title":"Pediatr Hematol Oncol J"},{"issue":"11","key":"7376_CR8","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1016\/j.ccell.2021.09.012","volume":"39","author":"APY Liu","year":"2021","unstructured":"Liu APY, Smith KS, Kumar R et al (2021) Serial assessment of measurable residual disease in medulloblastoma liquid biopsies. Cancer Cell 39(11):1519-1530.e4. https:\/\/doi.org\/10.1016\/j.ccell.2021.09.012","journal-title":"Cancer Cell"},{"issue":"4","key":"7376_CR9","doi-asserted-by":"publisher","first-page":"353","DOI":"10.3171\/2019.5.PEDS18381","volume":"24","author":"K Juraschka","year":"2019","unstructured":"Juraschka K, Taylor MD (2019) Medulloblastoma in the age of molecular subgroups: a review. J Neurosurg Pediatr 24(4):353\u2013363. https:\/\/doi.org\/10.3171\/2019.5.PEDS18381","journal-title":"J Neurosurg Pediatr"},{"issue":"9","key":"7376_CR10","first-page":"1757","volume":"21","author":"SP Meyers","year":"2000","unstructured":"Meyers SP, Wildenhain SL, Chang JK et al (2000) Postoperative evaluation for disseminated medulloblastoma involving the spine: contrast-enhanced MR findings, CSF cytologic analysis, timing of disease occurrence, and patient outcomes. AJNR Am J Neuroradiol 21(9):1757\u20131765","journal-title":"AJNR Am J Neuroradiol"},{"issue":"7","key":"7376_CR11","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1002\/pbc.25002","volume":"61","author":"V Ramaswamy","year":"2014","unstructured":"Ramaswamy V, Remke M, Shih D et al (2014) Duration of the pre-diagnostic interval in medulloblastoma is subgroup dependent. Pediatr Blood Cancer 61(7):1190\u20131194. https:\/\/doi.org\/10.1002\/pbc.25002","journal-title":"Pediatr Blood Cancer"},{"issue":"6","key":"7376_CR12","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.1007\/s13311-022-01273-0","volume":"19","author":"MA Lazow","year":"2022","unstructured":"Lazow MA, Palmer JD, Fouladi M, Salloum R (2022) Medulloblastoma in the modern era: review of contemporary trials, molecular advances, and updates in management. Neurotherapeutics 19(6):1733\u20131751. https:\/\/doi.org\/10.1007\/s13311-022-01273-0","journal-title":"Neurotherapeutics"},{"issue":"22","key":"7376_CR13","doi-asserted-by":"publisher","first-page":"2666","DOI":"10.4161\/cc.5.22.3446","volume":"5","author":"SC Clifford","year":"2006","unstructured":"Clifford SC, Lusher ME, Lindsey JC et al (2006) Wnt\/Wingless pathway activation and chromosome 6 loss characterize a distinct molecular sub-group of medulloblastomas associated with a favorable prognosis. Cell Cycle Georget Tex 5(22):2666\u20132670. https:\/\/doi.org\/10.4161\/cc.5.22.3446","journal-title":"Cell Cycle Georget Tex"},{"issue":"7","key":"7376_CR14","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.3174\/ajnr.A3990","volume":"35","author":"S Perreault","year":"2014","unstructured":"Perreault S, Ramaswamy V, Achrol AS et al (2014) MRI surrogates for molecular subgroups of medulloblastoma. AJNR Am J Neuroradiol 35(7):1263\u20131269. https:\/\/doi.org\/10.3174\/ajnr.A3990","journal-title":"AJNR Am J Neuroradiol"},{"issue":"12","key":"7376_CR15","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1038\/s41388-024-02967-9","volume":"43","author":"H Sheng","year":"2024","unstructured":"Sheng H, Li H, Zeng H et al (2024) Heterogeneity and tumoral origin of medulloblastoma in the single-cell era. Oncogene 43(12):839\u2013850. https:\/\/doi.org\/10.1038\/s41388-024-02967-9","journal-title":"Oncogene"},{"issue":"4","key":"7376_CR16","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1016\/j.ccell.2016.03.002","volume":"29","author":"TN Phoenix","year":"2016","unstructured":"Phoenix TN, Patmore DM, Boop S et al (2016) Medulloblastoma genotype dictates blood brain barrier phenotype. Cancer Cell 29(4):508\u2013522. https:\/\/doi.org\/10.1016\/j.ccell.2016.03.002","journal-title":"Cancer Cell"},{"issue":"1","key":"7376_CR17","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1038\/s41467-021-21883-0","volume":"12","author":"P Skowron","year":"2021","unstructured":"Skowron P, Farooq H, Cavalli FMG et al (2021) The transcriptional landscape of Shh medulloblastoma. Nat Commun 12(1):1749. https:\/\/doi.org\/10.1038\/s41467-021-21883-0","journal-title":"Nat Commun"},{"key":"7376_CR18","doi-asserted-by":"publisher","first-page":"566822","DOI":"10.3389\/fonc.2020.566822","volume":"10","author":"R Carta","year":"2020","unstructured":"Carta R, Del Baldo G, Miele E et al (2020) Cancer predisposition syndromes and medulloblastoma in the molecular era. Front Oncol 10:566822. https:\/\/doi.org\/10.3389\/fonc.2020.566822","journal-title":"Front Oncol"},{"issue":"5","key":"7376_CR19","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1002\/acn3.762","volume":"6","author":"O Menyh\u00e1rt","year":"2019","unstructured":"Menyh\u00e1rt O, Gy\u0151rffy B (2019) Principles of tumorigenesis and emerging molecular drivers of SHH-activated medulloblastomas. Ann Clin Transl Neurol 6(5):990\u20131005. https:\/\/doi.org\/10.1002\/acn3.762","journal-title":"Ann Clin Transl Neurol"},{"issue":"1","key":"7376_CR20","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1093\/neuonc\/noae178","volume":"27","author":"EC Schwalbe","year":"2025","unstructured":"Schwalbe EC, Lindsey JC, Danilenko M et al (2025) Molecular and clinical heterogeneity within MYC -family amplified medulloblastoma is associated with survival outcomes: a multicenter cohort study. Neuro-Oncol 27(1):222\u2013236. https:\/\/doi.org\/10.1093\/neuonc\/noae178","journal-title":"Neuro-Oncol"},{"issue":"7929","key":"7376_CR21","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1038\/s41586-022-05208-9","volume":"609","author":"KS Smith","year":"2022","unstructured":"Smith KS, Bihannic L, Gudenas BL et al (2022) Unified rhombic lip origins of group 3 and group 4 medulloblastoma. Nature 609(7929):1012\u20131020. https:\/\/doi.org\/10.1038\/s41586-022-05208-9","journal-title":"Nature"},{"issue":"2","key":"7376_CR22","doi-asserted-by":"publisher","first-page":"145","DOI":"10.3171\/2017.8.PEDS17264","volume":"21","author":"M Zapotocky","year":"2018","unstructured":"Zapotocky M, Mata-Mbemba D, Sumerauer D et al (2018) Differential patterns of metastatic dissemination across medulloblastoma subgroups. J Neurosurg Pediatr 21(2):145\u2013152. https:\/\/doi.org\/10.3171\/2017.8.PEDS17264","journal-title":"J Neurosurg Pediatr"},{"issue":"12","key":"7376_CR23","doi-asserted-by":"publisher","first-page":"1602","DOI":"10.1016\/S1470-2045(18)30532-1","volume":"19","author":"T Goschzik","year":"2018","unstructured":"Goschzik T, Schwalbe EC, Hicks D et al (2018) Prognostic effect of whole chromosomal aberration signatures in standard-risk, non-WNT\/non-SHH medulloblastoma: a retrospective, molecular analysis of the HIT-SIOP PNET 4 trial. Lancet Oncol 19(12):1602\u20131616. https:\/\/doi.org\/10.1016\/S1470-2045(18)30532-1","journal-title":"Lancet Oncol"},{"issue":"23","key":"7376_CR24","doi-asserted-by":"publisher","first-page":"5945","DOI":"10.3390\/cancers13235945","volume":"13","author":"C Seidel","year":"2021","unstructured":"Seidel C, Heider S, Hau P, Glasow A, Dietzsch S, Kortmann RD (2021) Radiotherapy in medulloblastoma-evolution of treatment, current concepts and future perspectives. Cancers 13(23):5945. https:\/\/doi.org\/10.3390\/cancers13235945","journal-title":"Cancers"},{"issue":"2","key":"7376_CR25","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1097\/00006123-199602000-00007","volume":"38","author":"AL Albright","year":"1996","unstructured":"Albright AL, Wisoff JH, Zeltzer PM, Boyett JM, Rorke LB, Stanley P (1996) Effects of medulloblastoma resections on outcome in children: a report from the Children\u2019s Cancer Group. Neurosurgery 38(2):265\u2013271. https:\/\/doi.org\/10.1097\/00006123-199602000-00007","journal-title":"Neurosurgery"},{"key":"7376_CR26","doi-asserted-by":"publisher","first-page":"245385","DOI":"10.1155\/2012\/245385","volume":"2012","author":"C Dufour","year":"2012","unstructured":"Dufour C, Beaugrand A, Pizer B et al (2012) Metastatic Medulloblastoma in Childhood: Chang\u2019s Classification Revisited. Int J Surg Oncol 2012:245385. https:\/\/doi.org\/10.1155\/2012\/245385","journal-title":"Int J Surg Oncol"},{"issue":"8","key":"7376_CR27","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1200\/JCO.2003.05.116","volume":"21","author":"RE Taylor","year":"2003","unstructured":"Taylor RE, Bailey CC, Robinson K et al (2003) Results of a randomized study of preradiation chemotherapy versus radiotherapy alone for nonmetastatic medulloblastoma: the International Society of Paediatric Oncology\/United Kingdom Children\u2019s Cancer Study Group PNET-3 Study. J Clin Oncol Off J Am Soc Clin Oncol 21(8):1581\u20131591. https:\/\/doi.org\/10.1200\/JCO.2003.05.116","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"6","key":"7376_CR28","doi-asserted-by":"publisher","first-page":"905","DOI":"10.3171\/jns.1991.74.6.0905","volume":"74","author":"JP Krischer","year":"1991","unstructured":"Krischer JP, Ragab AH, Kun L et al (1991) Nitrogen mustard, vincristine, procarbazine, and prednisone as adjuvant chemotherapy in the treatment of medulloblastoma. A Pediatric Oncology Group study. J Neurosurg 74(6):905\u2013909. https:\/\/doi.org\/10.3171\/jns.1991.74.6.0905","journal-title":"J Neurosurg"},{"issue":"4","key":"7376_CR29","doi-asserted-by":"publisher","first-page":"572","DOI":"10.3171\/jns.1990.72.4.0572","volume":"72","author":"AE Evans","year":"1990","unstructured":"Evans AE, Jenkin RD, Sposto R et al (1990) The treatment of medulloblastoma. Results of a prospective randomized trial of radiation therapy with and without CCNU, vincristine, and prednisone. J Neurosurg 72(4):572\u2013582. https:\/\/doi.org\/10.3171\/jns.1990.72.4.0572","journal-title":"J Neurosurg"},{"issue":"5","key":"7376_CR30","doi-asserted-by":"publisher","first-page":"690","DOI":"10.3171\/jns.1994.81.5.0690","volume":"81","author":"RJ Packer","year":"1994","unstructured":"Packer RJ, Sutton LN, Elterman R et al (1994) Outcome for children with medulloblastoma treated with radiation and cisplatin, CCNU, and vincristine chemotherapy. J Neurosurg 81(5):690\u2013698. https:\/\/doi.org\/10.3171\/jns.1994.81.5.0690","journal-title":"J Neurosurg"},{"issue":"1","key":"7376_CR31","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1093\/neuonc\/nos267","volume":"15","author":"RJ Packer","year":"2013","unstructured":"Packer RJ, Zhou T, Holmes E, Vezina G, Gajjar A (2013) Survival and secondary tumors in children with medulloblastoma receiving radiotherapy and adjuvant chemotherapy: results of Children\u2019s Oncology Group trial A9961. Neuro-Oncol 15(1):97\u2013103. https:\/\/doi.org\/10.1093\/neuonc\/nos267","journal-title":"Neuro-Oncol"},{"issue":"26","key":"7376_CR32","doi-asserted-by":"publisher","first-page":"3187","DOI":"10.1200\/JCO.2011.39.8719","volume":"30","author":"B Lannering","year":"2012","unstructured":"Lannering B, Rutkowski S, Doz F et al (2012) Hyperfractionated versus conventional radiotherapy followed by chemotherapy in standard-risk medulloblastoma: results from the randomized multicenter HIT-SIOP PNET 4 trial. J Clin Oncol Off J Am Soc Clin Oncol 30(26):3187\u20133193. https:\/\/doi.org\/10.1200\/JCO.2011.39.8719","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"24","key":"7376_CR33","doi-asserted-by":"publisher","first-page":"2685","DOI":"10.1200\/JCO.20.02730","volume":"39","author":"JM Michalski","year":"2021","unstructured":"Michalski JM, Janss AJ, Vezina LG et al (2021) Children\u2019s Oncology Group Phase III Trial of reduced-dose and reduced-volume radiotherapy with chemotherapy for newly diagnosed average-risk medulloblastoma. J Clin Oncol Off J Am Soc Clin Oncol 39(24):2685\u20132697. https:\/\/doi.org\/10.1200\/JCO.20.02730","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"10","key":"7376_CR34","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1016\/S1470-2045(06)70867-1","volume":"7","author":"A Gajjar","year":"2006","unstructured":"Gajjar A, Chintagumpala M, Ashley D et al (2006) Risk-adapted craniospinal radiotherapy followed by high-dose chemotherapy and stem-cell rescue in children with newly diagnosed medulloblastoma (St Jude Medulloblastoma-96): long-term results from a prospective, multicentre trial. Lancet Oncol 7(10):813\u2013820. https:\/\/doi.org\/10.1016\/S1470-2045(06)70867-1","journal-title":"Lancet Oncol"},{"issue":"9","key":"7376_CR35","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1001\/jamaoncol.2021.2224","volume":"7","author":"SES Leary","year":"2021","unstructured":"Leary SES, Packer RJ, Li Y et al (2021) Efficacy of carboplatin and isotretinoin in children with high-risk medulloblastoma. JAMA Oncol 7(9):1313\u20131321. https:\/\/doi.org\/10.1001\/jamaoncol.2021.2224","journal-title":"JAMA Oncol"},{"issue":"12","key":"7376_CR36","doi-asserted-by":"publisher","first-page":"2273","DOI":"10.1093\/neuonc\/noad114","volume":"25","author":"AS Kolodziejczak","year":"2023","unstructured":"Kolodziejczak AS, Guerrini-Rousseau L, Planchon JM et al (2023) Clinical outcome of pediatric medulloblastoma patients with Li-Fraumeni syndrome. Neuro Oncol 25(12):2273\u20132286. https:\/\/doi.org\/10.1093\/neuonc\/noad114","journal-title":"Neuro Oncol"},{"issue":"2","key":"7376_CR37","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1056\/NEJM199301143280203","volume":"328","author":"LS Constine","year":"1993","unstructured":"Constine LS, Woolf PD, Cann D et al (1993) Hypothalamic-pituitary dysfunction after radiation for brain tumors. N Engl J Med 328(2):87\u201394. https:\/\/doi.org\/10.1056\/NEJM199301143280203","journal-title":"N Engl J Med"},{"issue":"7","key":"7376_CR38","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/S1470-2045(04)01507-4","volume":"5","author":"RK Mulhern","year":"2004","unstructured":"Mulhern RK, Merchant TE, Gajjar A, Reddick WE, Kun LE (2004) Late neurocognitive sequelae in survivors of brain tumours in childhood. Lancet Oncol 5(7):399\u2013408. https:\/\/doi.org\/10.1016\/S1470-2045(04)01507-4","journal-title":"Lancet Oncol"},{"issue":"24","key":"7376_CR39","doi-asserted-by":"publisher","first-page":"3680","DOI":"10.3390\/diagnostics13243680","volume":"13","author":"N Mushtaq","year":"2023","unstructured":"Mushtaq N, Ul Ain R, Hamid SA, Bouffet E (2023) Evolution of systemic therapy in medulloblastoma including irradiation-sparing approaches. Diagnostics 13(24):3680. https:\/\/doi.org\/10.3390\/diagnostics13243680","journal-title":"Diagnostics"},{"issue":"12","key":"7376_CR40","doi-asserted-by":"publisher","first-page":"1862","DOI":"10.1093\/neuonc\/noaa102","volume":"22","author":"G Dhall","year":"2020","unstructured":"Dhall G, O\u2019Neil SH, Ji L et al (2020) Excellent outcome of young children with nodular desmoplastic medulloblastoma treated on \u201cHead Start\u201d III: a multi-institutional, prospective clinical trial. Neuro-Oncol 22(12):1862\u20131872. https:\/\/doi.org\/10.1093\/neuonc\/noaa102","journal-title":"Neuro-Oncol"},{"issue":"6","key":"7376_CR41","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1016\/S1470-2045(18)30204-3","volume":"19","author":"GW Robinson","year":"2018","unstructured":"Robinson GW, Rudneva VA, Buchhalter I et al (2018) Risk-adapted therapy for young children with medulloblastoma (SJYC07): therapeutic and molecular outcomes from a multicentre, phase 2 trial. Lancet Oncol 19(6):768\u2013784. https:\/\/doi.org\/10.1016\/S1470-2045(18)30204-3","journal-title":"Lancet Oncol"},{"issue":"23","key":"7376_CR42","doi-asserted-by":"publisher","first-page":"6077","DOI":"10.3390\/cancers13236077","volume":"13","author":"M Mynarek","year":"2021","unstructured":"Mynarek M, Milde T, Padovani L et al (2021) SIOP PNET5 MB Trial: history and concept of a molecularly stratified clinical trial of risk-adapted therapies for standard-risk medulloblastoma. Cancers 13(23):6077. https:\/\/doi.org\/10.3390\/cancers13236077","journal-title":"Cancers"},{"issue":"2","key":"7376_CR43","doi-asserted-by":"publisher","first-page":"374","DOI":"10.3390\/cancers14020374","volume":"14","author":"S Bailey","year":"2022","unstructured":"Bailey S, Andr\u00e9 N, Gandola L et al (2022) Clinical trials in high-risk medulloblastoma: evolution of the SIOP-Europe HR-MB Trial. Cancers 14(2):374. https:\/\/doi.org\/10.3390\/cancers14020374","journal-title":"Cancers"},{"issue":"8","key":"7376_CR44","doi-asserted-by":"publisher","first-page":"e29031","DOI":"10.1002\/pbc.29031","volume":"68","author":"AS Levy","year":"2021","unstructured":"Levy AS, Krailo M, Chi S et al (2021) Temozolomide with irinotecan versus temozolomide, irinotecan plus bevacizumab for recurrent medulloblastoma of childhood: report of a COG randomized Phase II screening trial. Pediatr Blood Cancer 68(8):e29031. https:\/\/doi.org\/10.1002\/pbc.29031","journal-title":"Pediatr Blood Cancer"},{"issue":"12","key":"7376_CR45","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.1001\/jamaoncol.2023.4437","volume":"9","author":"A Peyrl","year":"2023","unstructured":"Peyrl A, Chocholous M, Sabel M et al (2023) Sustained survival benefit in recurrent medulloblastoma by a metronomic antiangiogenic regimen. JAMA Oncol 9(12):1688. https:\/\/doi.org\/10.1001\/jamaoncol.2023.4437","journal-title":"JAMA Oncol"},{"key":"7376_CR46","doi-asserted-by":"publisher","first-page":"100861","DOI":"10.1016\/j.neo.2022.100861","volume":"35","author":"T Cooney","year":"2023","unstructured":"Cooney T, Lindsay H, Leary S, Wechsler-Reya R (2023) Current studies and future directions for medulloblastoma: a review from the pacific pediatric neuro-oncology consortium (PNOC) disease working group. Neoplasia 35:100861. https:\/\/doi.org\/10.1016\/j.neo.2022.100861","journal-title":"Neoplasia"},{"issue":"19","key":"7376_CR47","doi-asserted-by":"publisher","first-page":"4161","DOI":"10.1158\/1078-0432.CCR-22-1780","volume":"28","author":"M Remke","year":"2022","unstructured":"Remke M, Ramaswamy V (2022) WNT Medulloblastoma limbo: how low can we go? Clin Cancer Res 28(19):4161\u20134163. https:\/\/doi.org\/10.1158\/1078-0432.CCR-22-1780","journal-title":"Clin Cancer Res"},{"issue":"8","key":"7376_CR48","doi-asserted-by":"publisher","first-page":"896","DOI":"10.3390\/brainsci15080896","volume":"15","author":"DT Kim","year":"2025","unstructured":"Kim DT, Uloho-Okundaye M, Frederico SC, Guru S, Kim MJ, Chang SD (2025) Advancing medulloblastoma therapy in pediatrics: integrative molecular classification and emerging treatments. Brain Sci 15(8):896. https:\/\/doi.org\/10.3390\/brainsci15080896","journal-title":"Brain Sci"},{"issue":"2","key":"7376_CR49","doi-asserted-by":"publisher","first-page":"333","DOI":"10.3390\/cancers14020333","volume":"14","author":"L Gatto","year":"2022","unstructured":"Gatto L, Franceschi E, Tosoni A, Di Nunno V, Bartolini S, Brandes AA (2022) Molecular targeted therapies: time for a paradigm shift in medulloblastoma treatment? Cancers 14(2):333. https:\/\/doi.org\/10.3390\/cancers14020333","journal-title":"Cancers"},{"issue":"4","key":"7376_CR50","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.21873\/anticanres.14936","volume":"41","author":"H Maier","year":"2021","unstructured":"Maier H, Dalianis T, Kostopoulou ON (2021) New approaches in targeted therapy for medulloblastoma in children. Anticancer Res 41(4):1715\u20131726. https:\/\/doi.org\/10.21873\/anticanres.14936","journal-title":"Anticancer Res"},{"issue":"7","key":"7376_CR51","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1200\/JCO.20.01372","volume":"39","author":"A Gajjar","year":"2021","unstructured":"Gajjar A, Robinson GW, Smith KS et al (2021) Outcomes by clinical and molecular features in children with medulloblastoma treated with risk-adapted therapy: results of an International Phase III Trial (SJMB03). J Clin Oncol 39(7):822\u2013835. https:\/\/doi.org\/10.1200\/JCO.20.01372","journal-title":"J Clin Oncol"},{"issue":"23","key":"7376_CR52","doi-asserted-by":"publisher","first-page":"2936","DOI":"10.1200\/JCO.2012.43.9984","volume":"31","author":"NJ Tarbell","year":"2013","unstructured":"Tarbell NJ, Friedman H, Polkinghorn WR et al (2013) High-risk medulloblastoma: a pediatric oncology group randomized trial of chemotherapy before or after radiation therapy (POG 9031). J Clin Oncol 31(23):2936\u20132941. https:\/\/doi.org\/10.1200\/JCO.2012.43.9984","journal-title":"J Clin Oncol"},{"issue":"34","key":"7376_CR53","doi-asserted-by":"publisher","first-page":"4151","DOI":"10.1200\/JCO.2016.67.2428","volume":"34","author":"AO Von Bueren","year":"2016","unstructured":"Von Bueren AO, Kortmann RD, Von Hoff K et al (2016) Treatment of children and adolescents with metastatic medulloblastoma and prognostic relevance of clinical and biologic parameters. J Clin Oncol 34(34):4151\u20134160. https:\/\/doi.org\/10.1200\/JCO.2016.67.2428","journal-title":"J Clin Oncol"},{"issue":"1","key":"7376_CR54","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.pediatrneurol.2015.03.019","volume":"53","author":"BH Cohen","year":"2015","unstructured":"Cohen BH, Geyer JR, Miller DC et al (2015) Pilot study of intensive chemotherapy with peripheral hematopoietic cell support for children less than 3 years of age with malignant brain tumors, the CCG-99703 Phase I\/II Study. A report from the Children\u2019s Oncology Group. Pediatr Neurol 53(1):31\u201346. https:\/\/doi.org\/10.1016\/j.pediatrneurol.2015.03.019","journal-title":"Pediatr Neurol"},{"issue":"10","key":"7376_CR55","doi-asserted-by":"publisher","first-page":"2726","DOI":"10.1093\/neuonc\/noaf132","volume":"27","author":"C Mazewski","year":"2025","unstructured":"Mazewski C, Leary SES, Kang G et al (2025) Phase 3 randomized trial of high-dose methotrexate for young children with high-risk embryonal brain tumors: a report from the Children\u2019s Oncology Group. Neuro-oncol 27(10):2726\u20132737. https:\/\/doi.org\/10.1093\/neuonc\/noaf132","journal-title":"Neuro-oncol"},{"issue":"19","key":"7376_CR56","doi-asserted-by":"publisher","first-page":"4180","DOI":"10.1158\/1078-0432.CCR-22-0758","volume":"28","author":"T Gupta","year":"2022","unstructured":"Gupta T, Pervez S, Dasgupta A, Chatterjee A et al (2022) Omission of upfront craniospinal irradiation in patients with low-risk WNT-pathway medulloblastoma is associated with unacceptably high risk of neuraxial failure. Clin Cancer Res 28(19):4180\u20134185. https:\/\/doi.org\/10.1158\/1078-0432.CCR-22-0758","journal-title":"Clin Cancer Res"},{"issue":"24","key":"7376_CR57","doi-asserted-by":"publisher","first-page":"5031","DOI":"10.1158\/1078-0432.CCR-23-0348","volume":"29","author":"KJ Cohen","year":"2023","unstructured":"Cohen KJ, Munjapara V, Aguilera D et al (2023) A pilot study omitting radiation in the treatment of children with newly diagnosed WNT-activated medulloblastoma. Clin Cancer Res 29(24):5031\u20135037. https:\/\/doi.org\/10.1158\/1078-0432.CCR-23-0348","journal-title":"Clin Cancer Res"}],"container-title":["Child's Nervous System"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00381-026-07376-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00381-026-07376-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00381-026-07376-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T15:36:06Z","timestamp":1782574566000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00381-026-07376-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,27]]},"references-count":57,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["7376"],"URL":"https:\/\/doi.org\/10.1007\/s00381-026-07376-9","relation":{},"ISSN":["1433-0350"],"issn-type":[{"value":"1433-0350","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,27]]},"assertion":[{"value":"3 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"271"}}